Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

The Lancet. Oncology·2026
Same author

Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Nature·2026
Same author

ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming.

The Journal of clinical investigation·2026
Same author

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.

Cancer discovery·2026
Same author

TMPO promotes cellular dissemination and metastasis in circulating tumor cells.

bioRxiv : the preprint server for biology·2026
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 3, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

癌との戦いが進化している.

Daniel A Haber1, Nathanael S Gray, Jose Baselga

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA. haber@helix.mgh.harvard.edu

Cell
|April 5, 2011
PubMed
まとめ
この要約は機械生成です。

がん遺伝学と医薬品化学の最近の進歩は,がん治療に革命をもたらしています. 希少がんからの新しい分子洞察は,新たながん治療法を急速に形作っており,潜在的に転換点を示す可能性があります.

さらに関連する動画

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

関連する実験動画

Last Updated: Jun 3, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

科学分野:

  • 腫瘍学 腫瘍学
  • がん遺伝学 がん遺伝学
  • 薬用化学 薬用化学について

背景:

  • 基本的な科学的発見は,現在の進歩のための基礎を築きました.
  • がん遺伝学と医薬品化学の最近の進歩は収束しています.
  • 珍しい癌のサブセットにおける偶然の観察は,新しい洞察を促しました.

研究 の 目的:

  • 癌治療のための臨床研究におけるパラダイムシフトを強調する.
  • 新興がん治療法における分子洞察の急速な応用について議論する.
  • 癌治療戦略における転換点の可能性を探求する.

主な方法:

  • がん遺伝学の最近の進歩のレビュー.
  • 医薬品化学の発展を分析する.
  • 分子洞察の臨床実践への翻訳の検討.

主要な成果:

  • 癌遺伝学と医薬品化学の融合は,治療に革命をもたらしています.
  • 新興の治療法は,新しい分子洞察によって形作られている.
  • 臨床研究のパラダイムシフトが進行中です.

結論:

  • 基礎科学と臨床研究の統合は,著しい進歩を示しています.
  • 新興がん治療法により,患者の治療結果が改善されることが期待されています.
  • この収束は,がんとの闘いにおける重要な瞬間を象徴するかもしれない.